Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Alphavirus Replicon DNA Vectors Expressing Ebola GP and VP40 Antigens Induce Humoral and Cellular Immune Responses in Mice.

Ren S, Wei Q, Cai L, Yang X, Xing C, Tan F, Leavenworth JW, Liang S, Liu W.

Front Microbiol. 2018 Jan 10;8:2662. doi: 10.3389/fmicb.2017.02662. eCollection 2017.

2.

Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome.

Lim WC, Khan AM.

BMC Genomics. 2018 Jan 19;19(Suppl 1):42. doi: 10.1186/s12864-017-4328-8.

3.

Ebola Vaccine: How Far are we?

Sharma R, Jangid K, Anuradha.

J Clin Diagn Res. 2017 May;11(5):DE01-DE04. doi: 10.7860/JCDR/2017/22184.9863. Epub 2017 May 1. Review.

4.

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.

Cooper CL, Martins KA, Stronsky SM, Langan DP, Steffens J, Van Tongeren S, Bavari S.

Emerg Microbes Infect. 2017 Jun 7;6(6):e46. doi: 10.1038/emi.2017.31.

5.

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.

Bounds CE, Terry FE, Moise L, Hannaman D, Martin WD, De Groot AS, Suschak JJ, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2824-2836. doi: 10.1080/21645515.2017.1329788. Epub 2017 Jun 2.

6.

Updates on Treatment of Ebola Virus Disease.

Krishnasamy L, Saikumar C.

Malays J Med Sci. 2015 Nov;22(6):54-57.

7.

Ebola virus disease candidate vaccines under evaluation in clinical trials.

Martins KA, Jahrling PB, Bavari S, Kuhn JH.

Expert Rev Vaccines. 2016 Sep;15(9):1101-12. doi: 10.1080/14760584.2016.1187566. Epub 2016 May 27. Review.

8.

Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection.

Agrati C, Castilletti C, Casetti R, Sacchi A, Falasca L, Turchi F, Tumino N, Bordoni V, Cimini E, Viola D, Lalle E, Bordi L, Lanini S, Martini F, Nicastri E, Petrosillo N, Puro V, Piacentini M, Di Caro A, Kobinger GP, Zumla A, Ippolito G, Capobianchi MR.

Cell Death Dis. 2016 Mar 31;7:e2164. doi: 10.1038/cddis.2016.55.

9.

The Role of Cytokines and Chemokines in Filovirus Infection.

Bixler SL, Goff AJ.

Viruses. 2015 Oct 23;7(10):5489-507. doi: 10.3390/v7102892. Review.

10.

In silico prediction of Ebola Zaire GP(1,2) immuno-dominant epitopes for the Balb/c mouse.

Dutta DK, Rhodes K, Wood SC.

BMC Immunol. 2015 Oct 6;16:59. doi: 10.1186/s12865-015-0126-8.

11.

Molecular mechanisms of Ebola virus pathogenesis: focus on cell death.

Falasca L, Agrati C, Petrosillo N, Di Caro A, Capobianchi MR, Ippolito G, Piacentini M.

Cell Death Differ. 2015 Aug;22(8):1250-9. doi: 10.1038/cdd.2015.67. Epub 2015 May 29. Review.

12.

Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.

Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y.

Science. 2015 Apr 24;348(6233):439-42. doi: 10.1126/science.aaa4919. Epub 2015 Mar 26.

13.

Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ.

PLoS One. 2015 Mar 20;10(3):e0118881. doi: 10.1371/journal.pone.0118881. eCollection 2015.

14.

Mechanisms of immunity in post-exposure vaccination against Ebola virus infection.

Bradfute SB, Anthony SM, Stuthman KS, Ayithan N, Tailor P, Shaia CI, Bray M, Ozato K, Bavari S.

PLoS One. 2015 Mar 18;10(3):e0118434. doi: 10.1371/journal.pone.0118434. eCollection 2015.

15.

Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Bavari S, Bray M, Ozato K.

PLoS One. 2015 Feb 26;10(2):e0118345. doi: 10.1371/journal.pone.0118345. eCollection 2015.

16.

Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.

Lai KY, Ng WY, Cheng FF.

Infect Dis Poverty. 2014 Nov 28;3:43. doi: 10.1186/2049-9957-3-43. eCollection 2014.

17.

Ebola: translational science considerations.

Chiappelli F, Bakhordarian A, Thames AD, Du AM, Jan AL, Nahcivan M, Nguyen MT, Sama N, Manfrini E, Piva F, Rocha RM, Maida CA.

J Transl Med. 2015 Jan 16;13:11. doi: 10.1186/s12967-014-0362-3. Review.

18.

Biomarker correlates of survival in pediatric patients with Ebola virus disease.

McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF.

Emerg Infect Dis. 2014 Oct;20(10):1683-90. doi: 10.3201/eid2010.140430.

19.

Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.

Martins KA, Steffens JT, van Tongeren SA, Wells JB, Bergeron AA, Dickson SP, Dye JM, Salazar AM, Bavari S.

PLoS One. 2014 Feb 24;9(2):e89735. doi: 10.1371/journal.pone.0089735. eCollection 2014.

20.

Ebola virus vaccines: an overview of current approaches.

Marzi A, Feldmann H.

Expert Rev Vaccines. 2014 Apr;13(4):521-31. doi: 10.1586/14760584.2014.885841. Epub 2014 Feb 27. Review.

Supplemental Content

Support Center